GlassScriptPhysician profile
Mikhail Gendel
NPI 1235178344
$3,318.96
in general payments reported to CMS, 2019-2025
30 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $339 · 2021: $335 · 2022: $366 · 2023: $578 · 2024: $589 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $404.04 | 2019-2024 | Sublocade |
| Orexo US, INC. | $284.21 | 2019-2023 | Zubsolv |
| Gilead Sciences, INC. | $263.84 | 2023-2025 | Yeztugo |
| Novo Nordisk INC | $252.78 | 2021-2023 | Wegovy |
| Abbott Laboratories | $229.78 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $192.63 | 2019-2023 | Repatha, Otezla |
| Alkermes, INC. | $162.61 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $157.70 | 2019 | |
| Pfizer INC. | $138.40 | 2019-2022 | |
| Ascensia Diabetes Care US INC. | $123.24 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $121.84 | 2024 | Tezspire |
| Optinose US, INC. | $111.81 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $105.40 | 2023 | Quviviq |
| Allergan, INC. | $96.96 | 2019-2020 | |
| Lilly USA, LLC | $93.85 | 2024 | Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $88.18 | 2023-2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $84.62 | 2022 | |
| Glaxosmithkline, LLC. | $77.74 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Uswm, LLC | $71.85 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.88 | 2020-2021 | |
| Mylan Specialty L.P. | $24.70 | 2020 | |
| Mdd US Operations, LLC | $24.35 | 2020 | |
| Ucb, INC. | $23.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.02 | 2024 | |
| Seqirus USA INC | $19.96 | 2022 | |
| Merck Sharp & Dohme LLC | $17.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.44 | 2022 | |
| Shire North American Group INC | $16.03 | 2019 | |
| Medtronic USA, INC. | $14.98 | 2019 | |
| Cranial Technologies, INC | $13.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Gendel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.